The worldwide organ scarcity dilemma is being made worse by some of the recent advances in 3D bioprinting, which offer revolutionary opportunities for the repair of organs and tissues1. The method enables the accurate manufacturing of biological tissues by stacking bioinks including cells, biomaterials, and growth factors. Unlike traditional organ transplants, where donor availability is a significant limiting factor, 3D bioprinting may create patient-specific tissues and organs, lowering the risk of immunological rejection and the need for ongoing immunosuppressive therapy2. One of the most promising developments in 3D bioprinting is the capacity to print functioning circulatory networks, which are necessary for the survival and integration of huge tissue constructions3. The long-standing bottleneck has posed a barrier to establishing a consistent blood flow to maintain printed tissues. However, relatively newer techniques to bioprinting, such as sacrificial bio-inks that disintegrate to form vascular channels, show enormous potential4. These new methodologies allow for the creation of perfusable structures, which are more similar to real blood vessels and hence provide plentiful ways of distributing oxygen and nutrients to printed tissues, enhancing their survivability5. Recent technological advancements include the development of various technical features for bioprinting complex tissue structures, such as multi-cellular tissue constructs achieved through the use of multiple printheads on bioprinters for the simultaneous deposition of diverse cell types and biomaterials, resulting in increasingly realistic tissues that mimic natural forms6. For instance, individuals have effectively bioprinted tissues including the three primary cell types of the liver: hepatocytes, endothelial cells, and stromal cells in liver tissue engineering, therefore replicating the natural microarchitecture of the liver7. These tissues have shown in preclinical animals the ability to degrade poisons and synthesize essential proteins, representing a significant advancement toward the complete functioning of bioprinted organs8. Alongside the vascularized tissues, bioprinted skin grafts and cartilage for reconstructive surgery are advancing swiftly. Skin bioprinting is now undergoing clinical trials, and bioprinted grafts have shown superior healing efficiency and integration in burn treatment compared to native grafts9. Bioprinted cartilage has been used to mend joint deformities, exhibiting enhanced biomechanical qualities and improved tissue integration relative to traditional transplants10. The worldwide organ scarcity may now be dramatically mitigated by utilizing the platform of 3D bioprinting11. Bioprinting would reduce the dependency on accessible donor organs, which are most of the time inadequate, via the inclusion of a patient’s cells to build tissues and organs. Secondly, this approach minimizes the possibility of organ rejection by the immune system by the odds of rejection that are generally linked with conventional organ transplants. Further investigations indicate that ultimately completely functioning, complicated organs like kidneys or hearts will be bioprinted12. The idea is to someday generate organs that, once bioprinted, instantly need no more care before being transplanted – circumventing, thus, the entire paradigm of organ donors now in existence. However, the hurdles are massive: among others, regulatory and long-term studies certainly aren’t currently at an appropriate level. All the same, however, considerable development has been achieved in 3D bioprinting. With technical maturity in this respect, it is predicted that such may be deemed a revolutionary source that heralds a new era of organ transplantation, addresses the present organ scarcity issue, and improves the clinical results for millions of patients globally.
Vickram et al. (Tue,) studied this question.